{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:00:18Z","timestamp":1793228418333,"version":"4.5.0"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1038\/s41571-021-00593-y","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T13:14:49Z","timestamp":1641906889000},"page":"223-236","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":125,"title":["Single-cell profiling of tumour evolution in multiple myeloma \u2014 opportunities for precision medicine"],"prefix":"10.1038","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2535-3729","authenticated-orcid":false,"given":"Ankit K.","family":"Dutta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Alberge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romanos","family":"Sklavenitis-Pistofidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth D.","family":"Lightbody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0936-0753","authenticated-orcid":false,"given":"Gad","family":"Getz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7361-3092","authenticated-orcid":false,"given":"Irene M.","family":"Ghobrial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,11]]},"reference":[{"key":"593_CR1","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature09837","volume":"471","author":"MA Chapman","year":"2011","unstructured":"Chapman, M. A. et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467\u2013472 (2011).","journal-title":"Nature"},{"key":"593_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3997","volume":"5","author":"N Bolli","year":"2014","unstructured":"Bolli, N. et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat. Commun. 5, 2997 (2014).","journal-title":"Nat. Commun."},{"key":"593_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05058-y","volume":"9","author":"N Bolli","year":"2018","unstructured":"Bolli, N. et al. Genomic patterns of progression in smoldering multiple myeloma. Nat. Commun. 9, 3363 (2018).","journal-title":"Nat. Commun."},{"key":"593_CR4","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41375-018-0206-x","volume":"33","author":"AK Dutta","year":"2019","unstructured":"Dutta, A. K. et al. Subclonal evolution in disease progression from MGUS\/SMM to multiple myeloma is characterised by clonal stability. Leukemia 33, 457\u2013468 (2019).","journal-title":"Leukemia"},{"key":"593_CR5","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1182\/blood-2012-01-405977","volume":"120","author":"JB Egan","year":"2012","unstructured":"Egan, J. B. et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 120, 1060\u20131066 (2012).","journal-title":"Blood"},{"key":"593_CR6","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","volume":"120","author":"JJ Keats","year":"2012","unstructured":"Keats, J. J. et al. Clonal competition with alternating dominance in multiple myeloma. Blood 120, 1067\u20131076 (2012).","journal-title":"Blood"},{"key":"593_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","volume":"25","author":"JG Lohr","year":"2014","unstructured":"Lohr, J. G. et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25, 91\u2013101 (2014).","journal-title":"Cancer Cell"},{"key":"593_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00296-y","volume":"8","author":"L Rasche","year":"2017","unstructured":"Rasche, L. et al. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat. Commun. 8, 268 (2017).","journal-title":"Nat. Commun."},{"key":"593_CR9","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","volume":"33","author":"BA Walker","year":"2015","unstructured":"Walker, B. A. et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J. Clin. Oncol. 33, 3911\u20133920 (2015).","journal-title":"J. Clin. Oncol."},{"key":"593_CR10","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/leu.2013.199","volume":"28","author":"BA Walker","year":"2014","unstructured":"Walker, B. A. et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 28, 384\u2013390 (2014).","journal-title":"Leukemia"},{"key":"593_CR11","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/leu.2012.287","volume":"27","author":"N Weston-Bell","year":"2013","unstructured":"Weston-Bell, N. et al. Exome sequencing in tracking clonal evolution in multiple myeloma following therapy. Leukemia 27, 1188\u20131191 (2013).","journal-title":"Leukemia"},{"key":"593_CR12","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1038\/leu.2014.59","volume":"28","author":"S Zhao","year":"2014","unstructured":"Zhao, S. et al. Serial exome analysis of disease progression in premalignant gammopathies. Leukemia 28, 1548\u20131552 (2014).","journal-title":"Leukemia"},{"key":"593_CR13","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo, A. & Anderson, K. Multiple myeloma. N. Engl. J. Med. 364, 1046\u20131060 (2011).","journal-title":"N. Engl. J. Med."},{"key":"593_CR14","unstructured":"National Cancer Institute. Cancer Stat Facts: Myeloma. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html (2021)."},{"key":"593_CR15","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan, A. J. et al. Global burden of multiple myeloma: a systematic analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 4, 1221\u20131227 (2018).","journal-title":"JAMA Oncol."},{"key":"593_CR16","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/bjh.14649","volume":"178","author":"AK Dutta","year":"2017","unstructured":"Dutta, A. K., Hewett, D. R., Fink, J. L., Grady, J. P. & Zannettino, A. C. W. Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma. Br. J. Haematol. 178, 196\u2013208 (2017).","journal-title":"Br. J. Haematol."},{"key":"593_CR17","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","volume":"14","author":"S Manier","year":"2017","unstructured":"Manier, S. et al. Genomic complexity of multiple myeloma and its clinical implications. Nat. Rev. Clin. Oncol. 14, 100\u2013113 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"593_CR18","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3389\/fimmu.2019.01121","volume":"10","author":"BG Barwick","year":"2019","unstructured":"Barwick, B. G., Gupta, V. A., Vertino, P. M. & Boise, L. H. Cell of origin and genetic alterations in the pathogenesis of multiple myeloma. Front. Immunol. 10, 1121 (2019).","journal-title":"Front. Immunol."},{"key":"593_CR19","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1056\/NEJMoa01133202","volume":"346","author":"RA Kyle","year":"2002","unstructured":"Kyle, R. A. et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 346, 564\u2013569 (2002).","journal-title":"N. Engl. J. Med."},{"key":"593_CR20","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","volume":"113","author":"O Landgren","year":"2009","unstructured":"Landgren, O. et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113, 5412\u20135417 (2009).","journal-title":"Blood"},{"key":"593_CR21","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMoa070389","volume":"356","author":"RA Kyle","year":"2007","unstructured":"Kyle, R. A. et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 356, 2582\u20132590 (2007).","journal-title":"N. Engl. J. Med."},{"key":"593_CR22","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","volume":"113","author":"BM Weiss","year":"2009","unstructured":"Weiss, B. M., Abadie, J., Verma, P., Howard, R. S. & Kuehl, W. M. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113, 5418\u20135422 (2009).","journal-title":"Blood"},{"key":"593_CR23","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1038\/leu.2009.174","volume":"23","author":"R Fonseca","year":"2009","unstructured":"Fonseca, R. et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 23, 2210\u20132221 (2009).","journal-title":"Leukemia"},{"key":"593_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/0165-4608(94)00284-I","volume":"82","author":"JR Sawyer","year":"1995","unstructured":"Sawyer, J. R., Waldron, J. A., Jagannath, S. & Barlogie, B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet. Cytogenet. 82, 41\u201349 (1995).","journal-title":"Cancer Genet. Cytogenet."},{"key":"593_CR25","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","volume":"354","author":"RA Kyle","year":"2006","unstructured":"Kyle, R. A. et al. Prevalence of monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 354, 1362\u20131369 (2006).","journal-title":"N. Engl. J. Med."},{"key":"593_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0263-z","volume":"9","author":"D Murray","year":"2019","unstructured":"Murray, D. et al. Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement. Blood Cancer J. 9, 102 (2019).","journal-title":"Blood Cancer J."},{"key":"593_CR27","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/leu.2011.368","volume":"26","author":"AJ Greenberg","year":"2012","unstructured":"Greenberg, A. J., Vachon, C. M. & Rajkumar, S. V. Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites. Leukemia 26, 609\u2013614 (2012).","journal-title":"Leukemia"},{"key":"593_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0284-7","volume":"10","author":"CR Marinac","year":"2020","unstructured":"Marinac, C. R., Ghobrial, I. M., Birmann, B. M., Soiffer, J. & Rebbeck, T. R. Dissecting racial disparities in multiple myeloma. Blood Cancer J. 10, 19 (2020).","journal-title":"Blood Cancer J."},{"key":"593_CR29","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1182\/blood-2014-08-551549","volume":"124","author":"IM Ghobrial","year":"2014","unstructured":"Ghobrial, I. M. & Landgren, O. How I treat smoldering multiple myeloma. Blood 124, 3380\u20133388 (2014).","journal-title":"Blood"},{"key":"593_CR30","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15, e538\u2013e548 (2014).","journal-title":"Lancet Oncol."},{"key":"593_CR31","first-page":"578","volume":"25","author":"RA Kyle","year":"2011","unstructured":"Kyle, R. A., Buadi, F. & Rajkumar, S. V. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Oncology 25, 578\u2013586 (2011).","journal-title":"Oncology"},{"key":"593_CR32","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","volume":"132","author":"BA Walker","year":"2018","unstructured":"Walker, B. A. et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood 132, 587\u2013597 (2018).","journal-title":"Blood"},{"key":"593_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11680-1","volume":"10","author":"F Maura","year":"2019","unstructured":"Maura, F. et al. Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat. Commun. 10, 3835 (2019).","journal-title":"Nat. Commun."},{"key":"593_CR34","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1200\/JCO.20.00437","volume":"38","author":"M Bustoros","year":"2020","unstructured":"Bustoros, M. et al. Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression. J. Clin. Oncol. 38, 2380\u20132389 (2020).","journal-title":"J. Clin. Oncol."},{"key":"593_CR35","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41576-019-0180-9","volume":"21","author":"SS Ho","year":"2020","unstructured":"Ho, S. S., Urban, A. E. & Mills, R. E. Structural variation in the sequencing era. Nat. Rev. Genet. 21, 171\u2013189 (2020).","journal-title":"Nat. Rev. Genet."},{"key":"593_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22140-0","volume":"12","author":"B Oben","year":"2021","unstructured":"Oben, B. et al. Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. Nat. Commun. 12, 1861 (2021).","journal-title":"Nat. Commun."},{"key":"593_CR37","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1038\/s41375-018-0103-3","volume":"32","author":"PH Hoang","year":"2018","unstructured":"Hoang, P. H. et al. Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms. Leukemia 32, 2459\u20132470 (2018).","journal-title":"Leukemia"},{"key":"593_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09555-6","volume":"10","author":"BG Barwick","year":"2019","unstructured":"Barwick, B. G. et al. Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. Nat. Commun. 10, 1911 (2019).","journal-title":"Nat. Commun."},{"key":"593_CR39","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/ajh.24402","volume":"91","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar, S. V. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 91, 719\u2013734 (2016).","journal-title":"Am. J. Hematol."},{"key":"593_CR40","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.3324\/haematol.2017.163766","volume":"102","author":"A Mikulasova","year":"2017","unstructured":"Mikulasova, A. et al. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. Haematologica 102, 1617\u20131625 (2017).","journal-title":"Haematologica"},{"key":"593_CR41","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1182\/blood.V100.4.1417.h81602001417_1417_1424","volume":"100","author":"R Fonseca","year":"2002","unstructured":"Fonseca, R. et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 100, 1417\u20131424 (2002).","journal-title":"Blood"},{"key":"593_CR42","doi-asserted-by":"publisher","unstructured":"Leshchiner, I. et al. Comprehensive analysis of tumour initiation, spatial and temporal progression under multiple lines of treatment. Preprint at https:\/\/doi.org\/10.1101\/508127 (2019).","DOI":"10.1101\/508127"},{"key":"593_CR43","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nrg.2015.16","volume":"17","author":"C Gawad","year":"2016","unstructured":"Gawad, C., Koh, W. & Quake, S. R. Single-cell genome sequencing: current state of the science. Nat. Rev. Genet. 17, 175\u2013188 (2016).","journal-title":"Nat. Rev. Genet."},{"key":"593_CR44","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1038\/leu.2014.13","volume":"28","author":"L Melchor","year":"2014","unstructured":"Melchor, L. et al. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia 28, 1705\u20131715 (2014).","journal-title":"Leukemia"},{"key":"593_CR45","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41591-018-0269-2","volume":"24","author":"G Ledergor","year":"2018","unstructured":"Ledergor, G. et al. Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. Nat. Med. 24, 1867\u20131876 (2018).","journal-title":"Nat. Med."},{"key":"593_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0160-x","volume":"9","author":"JS Jang","year":"2019","unstructured":"Jang, J. S. et al. Molecular signatures of multiple myeloma progression through single cell RNA-seq. Blood Cancer J. 9, 2 (2019).","journal-title":"Blood Cancer J."},{"key":"593_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22804-x","volume":"12","author":"R Liu","year":"2021","unstructured":"Liu, R. et al. Co-evolution of tumor and immune cells during progression of multiple myeloma. Nat. Commun. 12, 2559 (2021).","journal-title":"Nat. Commun."},{"key":"593_CR48","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1182\/blood-2012-01-379024","volume":"120","author":"IM Ghobrial","year":"2012","unstructured":"Ghobrial, I. M. Myeloma as a model for the process of metastasis: implications for therapy. Blood 120, 20\u201330 (2012).","journal-title":"Blood"},{"key":"593_CR49","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41586-018-0703-0","volume":"563","author":"SY Shen","year":"2018","unstructured":"Shen, S. Y. et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature 563, 579\u2013583 (2018).","journal-title":"Nature"},{"key":"593_CR50","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","volume":"31","author":"MC Liu","year":"2020","unstructured":"Liu, M. C. et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann. Oncol. 31, 745\u2013759 (2020).","journal-title":"Ann. Oncol."},{"key":"593_CR51","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41586-019-1272-6","volume":"570","author":"S Cristiano","year":"2019","unstructured":"Cristiano, S. et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature 570, 385\u2013389 (2019).","journal-title":"Nature"},{"key":"593_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15086","volume":"8","author":"O Kis","year":"2017","unstructured":"Kis, O. et al. Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates. Nat. Commun. 8, 15086 (2017).","journal-title":"Nat. Commun."},{"key":"593_CR53","doi-asserted-by":"publisher","first-page":"363ra147","DOI":"10.1126\/scitranslmed.aac7037","volume":"8","author":"JG Lohr","year":"2016","unstructured":"Lohr, J. G. et al. Genetic interrogation of circulating multiple myeloma cells at single-cell resolution. Sci. Transl. Med. 8, 363ra147 (2016).","journal-title":"Sci. Transl. Med."},{"key":"593_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04001-5","volume":"9","author":"S Manier","year":"2018","unstructured":"Manier, S. et al. Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma. Nat. Commun. 9, 1691 (2018).","journal-title":"Nat. Commun."},{"key":"593_CR55","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1038\/s41375-018-0115-z","volume":"32","author":"G Guo","year":"2018","unstructured":"Guo, G. et al. Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. Leukemia 32, 1838\u20131841 (2018).","journal-title":"Leukemia"},{"key":"593_CR56","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.celrep.2017.03.025","volume":"19","author":"Y Mishima","year":"2017","unstructured":"Mishima, Y. et al. The mutational landscape of circulating tumor cells in multiple myeloma. Cell Rep. 19, 218\u2013224 (2017).","journal-title":"Cell Rep."},{"key":"593_CR57","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1038\/s41375-020-0883-0","volume":"34","author":"JJ Garces","year":"2020","unstructured":"Garces, J. J. et al. Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma. Leukemia 34, 3007\u20133018 (2020).","journal-title":"Leukemia"},{"key":"593_CR58","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41375-019-0588-4","volume":"34","author":"JJ Garces","year":"2020","unstructured":"Garces, J. J. et al. Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination. Leukemia 34, 589\u2013603 (2020).","journal-title":"Leukemia"},{"key":"593_CR59","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/bjh.15003","volume":"180","author":"B Foulk","year":"2018","unstructured":"Foulk, B. et al. Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disorders. Br. J. Haematol. 180, 71\u201381 (2018).","journal-title":"Br. J. Haematol."},{"key":"593_CR60","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1080\/10428190600647723","volume":"47","author":"MA Dimopoulos","year":"2006","unstructured":"Dimopoulos, M. A. et al. Macrofocal multiple myeloma in young patients: a distinct entity with favorable prognosis. Leuk. Lymphoma 47, 1553\u20131556 (2006).","journal-title":"Leuk. Lymphoma"},{"key":"593_CR61","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.3390\/ijms20051248","volume":"20","author":"L Rasche","year":"2019","unstructured":"Rasche, L., Kortum, K. M., Raab, M. S. & Weinhold, N. The impact of tumor heterogeneity on diagnostics and novel therapeutic strategies in multiple myeloma. Int. J. Mol. Sci. 20, 1248 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"593_CR62","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1182\/blood-2018-08-825356","volume":"133","author":"E Zamagni","year":"2019","unstructured":"Zamagni, E., Tacchetti, P. & Cavo, M. Imaging in multiple myeloma: how? When? Blood 133, 644\u2013651 (2019).","journal-title":"Blood"},{"key":"593_CR63","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1182\/blood-2016-09-692954","volume":"128","author":"MV Dhodapkar","year":"2016","unstructured":"Dhodapkar, M. V. MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood 128, 2599\u20132606 (2016).","journal-title":"Blood"},{"key":"593_CR64","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrclinonc.2017.197","volume":"15","author":"IM Ghobrial","year":"2018","unstructured":"Ghobrial, I. M., Detappe, A., Anderson, K. C. & Steensma, D. P. The bone-marrow niche in MDS and MGUS: implications for AML and MM. Nat. Rev. Clin. Oncol. 15, 219\u2013233 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"593_CR65","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/nature08851","volume":"464","author":"MH Raaijmakers","year":"2010","unstructured":"Raaijmakers, M. H. et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 464, 852\u2013857 (2010).","journal-title":"Nature"},{"key":"593_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9983","volume":"6","author":"MA Lawson","year":"2015","unstructured":"Lawson, M. A. et al. Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nat. Commun. 6, 8983 (2015).","journal-title":"Nat. Commun."},{"key":"593_CR67","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/nm.4202","volume":"22","author":"R Das","year":"2016","unstructured":"Das, R. et al. Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice. Nat. Med. 22, 1351\u20131357 (2016).","journal-title":"Nat. Med."},{"key":"593_CR68","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.neo.2017.09.004","volume":"19","author":"DR Hewett","year":"2017","unstructured":"Hewett, D. R. et al. DNA barcoding reveals habitual clonal dominance of myeloma plasma cells in the bone marrow microenvironment. Neoplasia 19, 972\u2013981 (2017).","journal-title":"Neoplasia"},{"key":"593_CR69","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","volume":"1","author":"O Zavidij","year":"2020","unstructured":"Zavidij, O. et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat. Cancer 1, 493\u2013506 (2020).","journal-title":"Nat. Cancer"},{"key":"593_CR70","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood.2018880930","volume":"134","author":"WH Khoo","year":"2019","unstructured":"Khoo, W. H. et al. A niche-dependent myeloid transcriptome signature defines dormant myeloma cells. Blood 134, 30\u201343 (2019).","journal-title":"Blood"},{"key":"593_CR71","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/d41573-019-00031-w","volume":"18","author":"P Wilcock","year":"2019","unstructured":"Wilcock, P. & Webster, R. The multiple myeloma drug market. Nat. Rev. Drug Discov. 18, 579\u2013580 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"593_CR72","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1158\/2159-8290.CD-13-0014","volume":"3","author":"M Andrulis","year":"2013","unstructured":"Andrulis, M. et al. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov. 3, 862\u2013869 (2013).","journal-title":"Cancer Discov."},{"key":"593_CR73","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1182\/blood-2014-11-568907","volume":"125","author":"B Paiva","year":"2015","unstructured":"Paiva, B., van Dongen, J. J. & Orfao, A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood 125, 3059\u20133068 (2015).","journal-title":"Blood"},{"key":"593_CR74","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","volume":"132","author":"A Perrot","year":"2018","unstructured":"Perrot, A. et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood 132, 2456\u20132464 (2018).","journal-title":"Blood"},{"key":"593_CR75","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","volume":"123","author":"J Martinez-Lopez","year":"2014","unstructured":"Martinez-Lopez, J. et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 123, 3073\u20133079 (2014).","journal-title":"Blood"},{"key":"593_CR76","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s00277-015-2344-9","volume":"94","author":"KM Kortum","year":"2015","unstructured":"Kortum, K. M. et al. Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P). Ann. Hematol. 94, 1205\u20131211 (2015).","journal-title":"Ann. Hematol."},{"key":"593_CR77","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/leu.2012.226","volume":"27","author":"F Magrangeas","year":"2013","unstructured":"Magrangeas, F. et al. Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia 27, 473\u2013481 (2013).","journal-title":"Leukemia"},{"key":"593_CR78","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","volume":"128","author":"N Weinhold","year":"2016","unstructured":"Weinhold, N. et al. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood 128, 1735\u20131744 (2016).","journal-title":"Blood"},{"key":"593_CR79","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1038\/s41375-018-0153-6","volume":"32","author":"J Corre","year":"2018","unstructured":"Corre, J. et al. Multiple myeloma clonal evolution in homogeneously treated patients. Leukemia 32, 2636\u20132647 (2018).","journal-title":"Leukemia"},{"key":"593_CR80","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3324\/haematol.2018.202200","volume":"104","author":"JR Jones","year":"2019","unstructured":"Jones, J. R. et al. Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. Haematologica 104, 1440\u20131450 (2019).","journal-title":"Haematologica"},{"key":"593_CR81","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1200\/JCO.19.01740","volume":"38","author":"S Lonial","year":"2020","unstructured":"Lonial, S. et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J. Clin. Oncol. 38, 1126\u20131137 (2020).","journal-title":"J. Clin. Oncol."},{"key":"593_CR82","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","volume":"17","author":"MV Mateos","year":"2016","unstructured":"Mateos, M. V. et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol. 17, 1127\u20131136 (2016).","journal-title":"Lancet Oncol."},{"key":"593_CR83","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa1300439","volume":"369","author":"MV Mateos","year":"2013","unstructured":"Mateos, M. V. et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N. Engl. J. Med. 369, 438\u2013447 (2013).","journal-title":"N. Engl. J. Med."},{"key":"593_CR84","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41591-021-01232-w","volume":"27","author":"YC Cohen","year":"2021","unstructured":"Cohen, Y. C. et al. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat. Med. 27, 491\u2013503 (2021).","journal-title":"Nat. Med."},{"key":"593_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15596-z","volume":"11","author":"A Acar","year":"2020","unstructured":"Acar, A. et al. Exploiting evolutionary steering to induce collateral drug sensitivity in cancer. Nat. Commun. 11, 1923 (2020).","journal-title":"Nat. Commun."},{"key":"593_CR86","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1182\/blood-2018-03-836718","volume":"132","author":"P Gomez-Bougie","year":"2018","unstructured":"Gomez-Bougie, P. et al. BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment. Blood 132, 2656\u20132669 (2018).","journal-title":"Blood"},{"key":"593_CR87","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","volume":"587","author":"LA Miles","year":"2020","unstructured":"Miles, L. A. et al. Single-cell mutation analysis of clonal evolution in myeloid malignancies. Nature 587, 477\u2013482 (2020).","journal-title":"Nature"},{"key":"593_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19119-8","volume":"11","author":"K Morita","year":"2020","unstructured":"Morita, K. et al. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat. Commun. 11, 5327 (2020).","journal-title":"Nat. Commun."},{"key":"593_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/srep44447","volume":"7","author":"P Shahi","year":"2017","unstructured":"Shahi, P., Kim, S. C., Haliburton, J. R., Gartner, Z. J. & Abate, A. R. Abseq: ultrahigh-throughput single cell protein profiling with droplet microfluidic barcoding. Sci. Rep. 7, 44447 (2017).","journal-title":"Sci. Rep."},{"key":"593_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21810-3","volume":"12","author":"B Demaree","year":"2021","unstructured":"Demaree, B. et al. Joint profiling of DNA and proteins in single cells to dissect genotype-phenotype associations in leukemia. Nat Commun. 12, 1583 (2021).","journal-title":"Nat Commun."},{"key":"593_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00366-3","volume":"10","author":"MV Mateos","year":"2020","unstructured":"Mateos, M. V. et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 10, 102 (2020).","journal-title":"Blood Cancer J."},{"key":"593_CR92","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","volume":"110","author":"E Perez-Persona","year":"2007","unstructured":"Perez-Persona, E. et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 110, 2586\u20132592 (2007).","journal-title":"Blood"},{"key":"593_CR93","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-16-3192","volume":"23","author":"X Feng","year":"2017","unstructured":"Feng, X. et al. Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma. Clin. Cancer Res. 23, 4290\u20134300 (2017).","journal-title":"Clin. Cancer Res."},{"key":"593_CR94","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1182\/blood-2010-04-279893","volume":"116","author":"G Gorgun","year":"2010","unstructured":"Gorgun, G. et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 116, 3227\u20133237 (2010).","journal-title":"Blood"},{"key":"593_CR95","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/2159-8290.CD-19-0759","volume":"11","author":"FJ Kohlhapp","year":"2021","unstructured":"Kohlhapp, F. J. et al. Venetoclax increases intratumoral effector T cells and antitumor efficacy in combination with immune checkpoint blockade. Cancer Discov. 11, 68\u201379 (2021).","journal-title":"Cancer Discov."},{"key":"593_CR96","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1182\/blood-2015-10-662320","volume":"127","author":"B Paiva","year":"2016","unstructured":"Paiva, B. et al. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis. Blood 127, 1151\u20131162 (2016).","journal-title":"Blood"},{"key":"593_CR97","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.27041","volume":"6","author":"A Regev","year":"2017","unstructured":"Regev, A. et al. The human cell atlas. eLife 6, e27041 (2017).","journal-title":"eLife"},{"key":"593_CR98","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/550451a","volume":"550","author":"O Rozenblatt-Rosen","year":"2017","unstructured":"Rozenblatt-Rosen, O., Stubbington, M. J. T., Regev, A. & Teichmann, S. A. The Human Cell Atlas: from vision to reality. Nature 550, 451\u2013453 (2017).","journal-title":"Nature"},{"key":"593_CR99","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","volume":"39","author":"A Bagaev","year":"2021","unstructured":"Bagaev, A. et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell 39, 845\u2013865.e7 (2021).","journal-title":"Cancer Cell"},{"key":"593_CR100","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41590-021-00931-3","volume":"22","author":"MME de Jong","year":"2021","unstructured":"de Jong, M. M. E. et al. The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape. Nat. Immunol. 22, 769\u2013780 (2021).","journal-title":"Nat. Immunol."},{"key":"593_CR101","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/leu.2012.237","volume":"27","author":"G Bianchi","year":"2013","unstructured":"Bianchi, G. et al. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia 27, 680\u2013685 (2013).","journal-title":"Leukemia"},{"key":"593_CR102","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.1200\/JCO.2005.03.159","volume":"23","author":"S Kumar","year":"2005","unstructured":"Kumar, S. et al. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. J. Clin. Oncol. 23, 5668\u20135674 (2005).","journal-title":"J. Clin. Oncol."},{"key":"593_CR103","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1182\/blood-2013-06-510453","volume":"122","author":"B Paiva","year":"2013","unstructured":"Paiva, B. et al. Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood 122, 3591\u20133598 (2013).","journal-title":"Blood"},{"key":"593_CR104","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1038\/leu.2014.98","volume":"28","author":"WI Gonsalves","year":"2014","unstructured":"Gonsalves, W. I. et al. Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. Leukemia 28, 2060\u20132065 (2014).","journal-title":"Leukemia"},{"key":"593_CR105","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.3324\/haematol.2016.158303","volume":"102","author":"M Granell","year":"2017","unstructured":"Granell, M. et al. Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. Haematologica 102, 1099\u20131104 (2017).","journal-title":"Haematologica"},{"key":"593_CR106","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1182\/blood.2019002610","volume":"134","author":"L Sanoja-Flores","year":"2019","unstructured":"Sanoja-Flores, L. et al. Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. Blood 134, 2218\u20132222 (2019).","journal-title":"Blood"},{"key":"593_CR107","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2005-05-1858","volume":"106","author":"GS Nowakowski","year":"2005","unstructured":"Nowakowski, G. S. et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood 106, 2276\u20132279 (2005).","journal-title":"Blood"},{"key":"593_CR108","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s42256-020-0153-x","volume":"2","author":"LL Zeune","year":"2020","unstructured":"Zeune, L. L. et al. Deep learning of circulating tumour cells. Nat. Mach. Intell. 2, 124\u2013133 (2020).","journal-title":"Nat. Mach. Intell."},{"key":"593_CR109","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1126\/science.1253533","volume":"345","author":"M Yu","year":"2014","unstructured":"Yu, M. et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 345, 216\u2013220 (2014).","journal-title":"Science"},{"key":"593_CR110","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/leu.2015.184","volume":"30","author":"C Touzeau","year":"2016","unstructured":"Touzeau, C. et al. BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia 30, 761\u2013764 (2016).","journal-title":"Leukemia"},{"key":"593_CR111","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41586-020-2922-4","volume":"587","author":"KJ Travaglini","year":"2020","unstructured":"Travaglini, K. J. et al. A molecular cell atlas of the human lung from single-cell RNA sequencing. Nature 587, 619\u2013625 (2020).","journal-title":"Nature"},{"key":"593_CR112","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1158\/2159-8290.CD-17-1415","volume":"8","author":"TR Rebbeck","year":"2018","unstructured":"Rebbeck, T. R. et al. Precision prevention and early detection of cancer: fundamental principles. Cancer Discov. 8, 803\u2013811 (2018).","journal-title":"Cancer Discov."},{"key":"593_CR113","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41588-018-0202-0","volume":"50","author":"C Turnbull","year":"2018","unstructured":"Turnbull, C., Sud, A. & Houlston, R. S. Cancer genetics, precision prevention and a call to action. Nat. Genet. 50, 1212\u20131218 (2018).","journal-title":"Nat. Genet."},{"key":"593_CR114","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/23808993.2019.1578172","volume":"4","author":"D Auclair","year":"2019","unstructured":"Auclair, D., Lonial, S., Anderson, K. C. & Kumar, S. K. Precision medicine in multiple myeloma: are we there yet? Expert Rev. Precis. Med. Drug Dev. 4, 51\u201353 (2019).","journal-title":"Expert Rev. Precis. Med. Drug Dev."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-021-00593-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-021-00593-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-021-00593-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T22:08:53Z","timestamp":1666562933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-021-00593-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,11]]},"references-count":114,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["593"],"URL":"https:\/\/doi.org\/10.1038\/s41571-021-00593-y","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,11]]},"assertion":[{"value":"13 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.K.D. and E.D.L. have acted as consultants for and received honoraria from Menarini Silicon Biosystems. G.G. receives research funding from IBM and Pharmacyclics; is an inventor on patent applications related to ABSOLUTE, MSIDetect, MSMutSig, MSMuTect, MutSig, MuTect, POLYSOLVER and TensorQTL; and is a founder, consultant and holds privately held equity in Scorpion Therapeutics. I.M.G. is a consultant for AbbVie, Adaptive, Aptitude, Bristol Myers Squibb, Cellectar, Curio Science, Genentech, GNS, GSK, Janssen, Karyopharm, Medscape, Oncopeptides, Sanofi, and Takeda and has received honoraria from Aptitude. J.-B.A. and R.S.-P. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}